Global Chronic Idiopathic Myelofibrosis 麻豆原创 Research Report 2023

Publication ID:

PB504231066

Publication Date:

April 12, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Idiopathic myelofibrosis is a chronic myelo-proliferative disorder and characterized by abnormal mutation of stem cells. This abnormal mutation of stem cells and excessive production of platelets result in development of fibrous tissues within the bone-marrow. This factor would ultimately negatively affect on the development of white blood cells (WBCs), red blood cells (RBCs) and platelets. The condition of idiopathic myelofibrosis may ultimately lead to the risk of acute myelogenous leukemia. Risk of idiopathic myelofibrosis is more in geriatric population as compared to children and adult population. Patients may develop symptoms such as weakness, weight loss, night sweats, hypertension and others. Blood chemistry tests, bone marrow aspiration, molecular testing and biopsy are useful diagnostic tools to diagnose and detect chronic idiopathic myelofibrosis. Patients with idiopathic myelofibrosis are advised to take drugs like hydroxyurea, interferon alfa, androgens, prednisone and others in order to treat this disorder. In addition, stem cell transplant and splenectomy is performed by physicians in severe cases of chronic idiopathic myelofibrosis.
Highlights
The global Chronic Idiopathic Myelofibrosis market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The market of chronic idiopathic myelofibrosis is majorly driven by consistent efforts of key players to develop new and effective therapeutics. In addition, strategic collaboration and acquisition adopted by key players will further act as a driving factor for this market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chronic Idiopathic Myelofibrosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Idiopathic Myelofibrosis.
The Chronic Idiopathic Myelofibrosis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Chronic Idiopathic Myelofibrosis market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Idiopathic Myelofibrosis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
S-BIO
YM BioSciences
Sanofi
Onyx Pharmaceuticals
Segment by Type
Chemotherapy
Biological Therapy
Others
Segment by Application
Hospitals
Clinics
Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Idiopathic Myelofibrosis companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Chronic Idiopathic Myelofibrosis 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Biological Therapy
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Chronic Idiopathic Myelofibrosis 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Idiopathic Myelofibrosis 麻豆原创 Perspective (2018-2029)
2.2 Chronic Idiopathic Myelofibrosis Growth Trends by Region
2.2.1 Global Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chronic Idiopathic Myelofibrosis Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Chronic Idiopathic Myelofibrosis Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Chronic Idiopathic Myelofibrosis 麻豆原创 Dynamics
2.3.1 Chronic Idiopathic Myelofibrosis Industry Trends
2.3.2 Chronic Idiopathic Myelofibrosis 麻豆原创 Drivers
2.3.3 Chronic Idiopathic Myelofibrosis 麻豆原创 Challenges
2.3.4 Chronic Idiopathic Myelofibrosis 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Idiopathic Myelofibrosis Players by Revenue
3.1.1 Global Top Chronic Idiopathic Myelofibrosis Players by Revenue (2018-2023)
3.1.2 Global Chronic Idiopathic Myelofibrosis Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Chronic Idiopathic Myelofibrosis 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Idiopathic Myelofibrosis Revenue
3.4 Global Chronic Idiopathic Myelofibrosis 麻豆原创 Concentration Ratio
3.4.1 Global Chronic Idiopathic Myelofibrosis 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Idiopathic Myelofibrosis Revenue in 2022
3.5 Chronic Idiopathic Myelofibrosis Key Players Head office and Area Served
3.6 Key Players Chronic Idiopathic Myelofibrosis Product Solution and Service
3.7 Date of Enter into Chronic Idiopathic Myelofibrosis 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Idiopathic Myelofibrosis Breakdown Data by Type
4.1 Global Chronic Idiopathic Myelofibrosis Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Chronic Idiopathic Myelofibrosis Forecasted 麻豆原创 Size by Type (2024-2029)
5 Chronic Idiopathic Myelofibrosis Breakdown Data by Application
5.1 Global Chronic Idiopathic Myelofibrosis Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Chronic Idiopathic Myelofibrosis Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Chronic Idiopathic Myelofibrosis 麻豆原创 Size (2018-2029)
6.2 North America Chronic Idiopathic Myelofibrosis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Country (2018-2023)
6.4 North America Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Idiopathic Myelofibrosis 麻豆原创 Size (2018-2029)
7.2 Europe Chronic Idiopathic Myelofibrosis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Country (2018-2023)
7.4 Europe Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Idiopathic Myelofibrosis 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Chronic Idiopathic Myelofibrosis 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Idiopathic Myelofibrosis 麻豆原创 Size (2018-2029)
9.2 Latin America Chronic Idiopathic Myelofibrosis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Idiopathic Myelofibrosis 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Chronic Idiopathic Myelofibrosis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Chronic Idiopathic Myelofibrosis 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 S-BIO
11.1.1 S-BIO Company Detail
11.1.2 S-BIO Business Overview
11.1.3 S-BIO Chronic Idiopathic Myelofibrosis Introduction
11.1.4 S-BIO Revenue in Chronic Idiopathic Myelofibrosis Business (2018-2023)
11.1.5 S-BIO Recent Development
11.2 YM BioSciences
11.2.1 YM BioSciences Company Detail
11.2.2 YM BioSciences Business Overview
11.2.3 YM BioSciences Chronic Idiopathic Myelofibrosis Introduction
11.2.4 YM BioSciences Revenue in Chronic Idiopathic Myelofibrosis Business (2018-2023)
11.2.5 YM BioSciences Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Chronic Idiopathic Myelofibrosis Introduction
11.3.4 Sanofi Revenue in Chronic Idiopathic Myelofibrosis Business (2018-2023)
11.3.5 Sanofi Recent Development
11.4 Onyx Pharmaceuticals
11.4.1 Onyx Pharmaceuticals Company Detail
11.4.2 Onyx Pharmaceuticals Business Overview
11.4.3 Onyx Pharmaceuticals Chronic Idiopathic Myelofibrosis Introduction
11.4.4 Onyx Pharmaceuticals Revenue in Chronic Idiopathic Myelofibrosis Business (2018-2023)
11.4.5 Onyx Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

S-BIO
YM BioSciences
Sanofi
Onyx Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.